Sanofi-Aventis has told a gathering of the American Diabetes Association that its blockbuster weight drug Acomplia helped overweight diabetics control blood sugar levels and lose weight. Twice as many patients taking Acomplia were able to manage levels of HbA1c compared to patients on a placebo. That's good news for Sanofi, which is touting Acomplia -- rimonabant -- as a drug that can treat a cluster of ailments. Analysts peg potential Acomplia sales at $1 billion per year. The study included people with type 2 diabetes.
- read this story from the International Herald Tribune for more